David Melisi, MD, PhD, University of Verona, Verona, Italy, discusses current targeted therapies being investigated for pancreatic cancer, including RAS inhibitors for patients with KRAS mutations, highlighting their potential for being used in personalized medicine. Patients with other mutations, such as rearrangements of RET and ALK, can benefit from other existing targeting agents. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
9 июл 2024
